Invivyd (NASDAQ:IVVD) Shares Gap Up – What’s Next?

Invivyd, Inc. (NASDAQ:IVVD) shares gapped up prior to trading on Thursday . The stock had previously closed at $2.40, but opened at $2.52. Invivyd shares last traded at $2.4550, with a volume of 529,678 shares trading hands.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IVVD shares. HC Wainwright increased their price objective on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. BTIG Research started coverage on shares of Invivyd in a report on Monday, December 22nd. They issued a “buy” rating and a $10.00 price target on the stock. D Boral Capital cut shares of Invivyd from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Finally, Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.00.

Invivyd Trading Up 2.3%

The stock has a market capitalization of $572.31 million, a PE ratio of -5.24 and a beta of 0.61. The business’s 50-day moving average is $2.27 and its two-hundred day moving average is $1.49.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%.The company had revenue of $13.13 million for the quarter, compared to analyst estimates of $12.00 million. On average, analysts predict that Invivyd, Inc. will post -1.64 EPS for the current year.

Insiders Place Their Bets

In other news, Director Kevin F. Mclaughlin acquired 50,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was bought at an average price of $2.50 per share, with a total value of $125,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $125,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 25.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Invivyd

A number of large investors have recently added to or reduced their stakes in IVVD. RA Capital Management L.P. purchased a new stake in Invivyd during the 3rd quarter worth $18,831,000. ADAR1 Capital Management LLC purchased a new stake in shares of Invivyd during the third quarter worth about $8,108,000. Vanguard Group Inc. lifted its stake in shares of Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after acquiring an additional 1,834,970 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Invivyd in the third quarter worth about $894,000. Finally, AQR Capital Management LLC boosted its holdings in Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares during the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.